ATE524192T1 - Zur immunmodulation geeignetes peptid - Google Patents

Zur immunmodulation geeignetes peptid

Info

Publication number
ATE524192T1
ATE524192T1 AT02775191T AT02775191T ATE524192T1 AT E524192 T1 ATE524192 T1 AT E524192T1 AT 02775191 T AT02775191 T AT 02775191T AT 02775191 T AT02775191 T AT 02775191T AT E524192 T1 ATE524192 T1 AT E524192T1
Authority
AT
Austria
Prior art keywords
immune modulation
peptide suitable
induction
peptides
cancer
Prior art date
Application number
AT02775191T
Other languages
English (en)
Inventor
Britta Hardy
Annat Raiter
Leah Klapper
Original Assignee
Cure Tech Ltd
Mor Research Applic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cure Tech Ltd, Mor Research Applic Ltd filed Critical Cure Tech Ltd
Application granted granted Critical
Publication of ATE524192T1 publication Critical patent/ATE524192T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02775191T 2001-10-15 2002-10-15 Zur immunmodulation geeignetes peptid ATE524192T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14592601A IL145926A0 (en) 2001-10-15 2001-10-15 Peptide epitopes of mimotopes useful in immunomodulation
PCT/IL2002/000831 WO2003033644A2 (en) 2001-10-15 2002-10-15 Peptide useful in immunomodulation

Publications (1)

Publication Number Publication Date
ATE524192T1 true ATE524192T1 (de) 2011-09-15

Family

ID=11075830

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02775191T ATE524192T1 (de) 2001-10-15 2002-10-15 Zur immunmodulation geeignetes peptid

Country Status (7)

Country Link
US (3) US7122372B2 (de)
EP (1) EP1469869B1 (de)
AT (1) ATE524192T1 (de)
AU (1) AU2002341375A1 (de)
ES (1) ES2373377T3 (de)
IL (3) IL145926A0 (de)
WO (1) WO2003033644A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP3757130A1 (de) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
AU2014340075A1 (en) * 2013-10-22 2016-05-19 Bioincept, Llc PIF-transfected cells and methods of use
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
AU2015210750B2 (en) 2014-01-31 2020-08-20 Children's Medical Center Corporation Antibody molecules to TIM-3 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CN107106666A (zh) 2014-07-17 2017-08-29 布莱恩·J·赫尔尼奇 用于基于免疫的治疗的免疫原性mhcii类肽的鉴定
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
EP3325005A4 (de) * 2015-07-17 2019-03-27 Brian J. Czerniecki Identifikation von immunogenen mhc-klasse-ii-peptiden für immunbasierte therapie
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EP3341006A4 (de) 2015-08-28 2019-03-13 BioIncept LLC Zusammensetzungen und verfahren zur behandlung von nervenschäden
EP3341739A4 (de) 2015-08-28 2019-07-10 BioIncept LLC Mutierte peptide und verfahren zur behandlung von subjekten damit
CN112745382B (zh) * 2021-01-22 2022-05-31 浙江辉肽生命健康科技有限公司 具有氨基酸结构ltvinqtqkenlr的生物活性肽及其制备方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3117934A1 (de) 1981-05-06 1982-12-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Neues peptid, verfahren zu seiner gewinnung und dieses enthaltendes arzneimittel
JPS60136596A (ja) 1983-12-26 1985-07-20 Suntory Ltd ペプチド及びこれを有効成分とする利尿剤
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
US5439688A (en) 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5298246A (en) 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
JP2925391B2 (ja) 1992-01-09 1999-07-28 サントリー株式会社 Ａｒｄｓ治療用医薬組成物
DE69319728T2 (de) 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
JP3908271B2 (ja) 1993-03-05 2007-04-25 エピミューン，インコーポレイティド Ｈｌａ−ａ２．１結合ペプチドおよびそれらの使用
KR950015111B1 (ko) * 1993-04-27 1995-12-22 안성애 가스함포캔디의 제조방법 및 장치
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
IL108501A (en) 1994-01-31 1998-10-30 Mor Research Applic Ltd Antibodies and pharmaceutical compositions containing them
RU2107692C1 (ru) 1995-06-07 1998-03-27 Дейгин Владислав Исакович Пептид и способ его получения
JPH0827018A (ja) 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
JPH08138744A (ja) * 1994-11-16 1996-05-31 Fuji Photo Film Co Ltd 非水二次電池
US5877155A (en) 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US6833447B1 (en) * 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
US6373223B1 (en) 2000-11-21 2002-04-16 Nagano Japan Radio Co., Ltd. Voltage equalizing apparatus and voltage equalizing method for battery devices
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation

Also Published As

Publication number Publication date
ES2373377T3 (es) 2012-02-02
WO2003033644A3 (en) 2004-07-29
IL160988A (en) 2010-11-30
US7122372B2 (en) 2006-10-17
US7329639B2 (en) 2008-02-12
AU2002341375A1 (en) 2003-04-28
US20080175855A1 (en) 2008-07-24
EP1469869A2 (de) 2004-10-27
IL145926A0 (en) 2002-07-25
WO2003033644A2 (en) 2003-04-24
US20060210573A1 (en) 2006-09-21
US7745397B2 (en) 2010-06-29
IL160988A0 (en) 2004-08-31
EP1469869A4 (de) 2006-07-12
EP1469869B1 (de) 2011-09-14
US20050003397A1 (en) 2005-01-06

Similar Documents

Publication Publication Date Title
EP1469869A4 (de) Zur immunmodulation geeignetes peptid
Garaci et al. Thymosin α1 in combination with cytokines and chemotherapy for the treatment of cancer
TR200102577T2 (tr) Kanser Tedavisi için Casb616 Polipeptid ve Polinücleotidlerin kullanımı
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
AU2003242305A1 (en) Hla-a24-restricted cancer antigen peptide
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
ATE255128T1 (de) Peptid-immitierende substanzen in der krebstherapie
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
AU2003256912A8 (en) Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
EA200300092A1 (ru) Применение лигандов молекул мнс класса ii в качестве адъювантов для вакцинации и lag-3 в лечении злокачественных опухолей
GB2255093A (en) Hiv-1 core protein fragments
AU2003267401A1 (en) Novel mhc ii associated peptides
HUP0300054A1 (hu) Daganatspecifikus állati fehérjék
EP1536006A4 (de) Krebsantigene und deren nutzung
Rizza et al. Cytokines as natural adjuvants for vaccines: where are we now?
GR3035152T3 (en) Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens
Maeurer et al. Human intestinal V delta 1+ T cells obtained from patients with colon cancer respond exclusively to SEB but not to SEA
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
NZ331398A (en) Tumor rejection antigens presented by hla-b44 molecules, and uses thereof
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
MXPA03005031A (es) Composicion vacunal que contiene factor de crecimiento transformante alfa.
ITRM960687A1 (it) Composizione immunogenica da tlp
WO2003042700A3 (en) Breast cancer associated polypeptide
EP0674526A4 (de) Impfung mit peptiden von mhc klasse ii molekülen zur behandlung von autoimmunkrankheiten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1469869

Country of ref document: EP